ArticleMolecular medicine (Cambridge, Mass.)2026
Hematopoietic stem and progenitor cells derived platelet lysate promotes diabetic wound healing.
Article in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundDiabetic wounds represent an escalating clinical challenge driven by the rising global prevalence of diabetes and the lack of effective treatments. Platelets serve as natural reservoirs of diverse growth factors, holding considerable promise for promoting tissue regeneration and wound repair. However, current platelet-derived therapies are constrained by donor dependence, protocol variability, and inconsistent product quality.
methodsThis study established an efficient in vitro protocol for generating functional platelets from human hematopoietic stem and progenitor cells (HSPCs). These regenerative platelets were subsequently lysed to produce induced human platelet lysate (ihPL). The contents of key growth factors in ihPL and human peripheral blood platelet lysate (hPL) were compared by enzyme-linked immunosorbent assay (ELISA). We established diabetic mice wound model to evaluate the therapeutic efficacy of ihPL on wound healing. Furthermore, in vitro experiments assessed the effects of ihPL on dermal fibroblasts proliferation, migration, and collagen synthesis. Transcriptome sequencing and Western blot (WB) were employed to elucidate the underlying signaling pathways.
resultsHSPCs differentiation into megakaryocytes exceeded 80%, with a subsequent platelet production efficiency of 38.3% ± 5.35%. ELISA revealed that the concentrations of fibroblast growth factor (140.1 ± 0.986 vs. 1.0 ± 0.008) and vascular endothelial growth factor (12.74 ± 5.280 vs. 1.0 ± 0.276) were significantly elevated in ihPL compared with hPL. In diabetic mice, ihPL (89.44% ± 9.83%), hPL (73.60% ± 12.21%), and epidermal growth factor (EGF, 59.72% ± 12.87%) significantly accelerated wound closure compared with the vehicle control group (43.53% ± 16.09%) at day 14 (P < 0.05). Notably, ihPL demonstrated superior efficacy relative to both hPL and EGF (P < 0.05). Histological analysis and Optical coherence tomography angiography confirmed enhanced extracellular matrix deposition and angiogenesis with ihPL versus vehicle control. Furthermore, ihPL significantly promoted dermal fibroblasts proliferation, migration, and collagen synthesis in vitro. Transcriptome analyses indicated activation of multiple tissue regeneration-associated signaling pathways and WB further confirmed the upregulation of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway representing a potential underlying mechanism.
conclusionThis study establishes a standardized, donor-independent, and immunologically safer cell-based therapeutic strategy for diabetic wound management, with considerable potential for clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.